Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 25, 2025International Journal of Medical Science and Clinical Research StudiesOpen Access

BRAF Wild-Type Melanomas with NF1 Mutations: Implications for MEK Inhibitor Therapy in Specific Molecular Subgroups

View Full Paper
Ask AI
Bookmark
Share

Authors

LCLizeth Montelongo CedilloJLJuan Camilo LópezEBEmanuel Chew Bonilla

Discussion

Loading...

Member takes

Overview

This analysis uncovers the challenges of treating NF1-mutated BRAF wild-type melanomas with MEK inhibitors, suggesting predictive biomarkers and resistance mechanisms.

Key Points

  • NF1 mutations in BRAF wild-type melanomas suggest unique treatment responses to MEK inhibitor therapy.
  • Constitutive MAPK pathway activation in NF1-deficient melanomas indicates potential clinical efficacy of MEK inhibitors.
  • Understanding genomic heterogeneity helps in stratifying patients for effective MEK inhibitor treatment.
  • Resistance mechanisms in NF1-mutated, BRAF wild-type melanoma highlight the need for novel combinatorial strategies.

Cite This Study

Cedillo et al. (2025) studied this question.

synapsesocial.com/papers/68d5d0d7ddad3c16d4635b0ehttps://doi.org/10.47191/ijmscrs/v5-i09-19
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review2025 · 18 citations
  2. 2Data from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma2025
  3. 3Neurofibromatosis Type 1 and MEK Inhibition: A Comprehensive Review with Focus on Selumetinib Therapy2025
  4. 4Tumor heterogeneity underlies clinical outcome and MEK inhibitor response in somatic NF1-mutant glioblastoma.2025
  5. 5NRas Nanoclusters Mediate Crosstalk Between BRAF/ERK and PI3K/AKT Signaling in Melanoma Cells2025